• COX-2 Inhibitors May Improve Cancer Immunotherapy Response
  • Opdivo, Yervoy, and Keytruda May Induce Rare Adverse Reactions Affecting the Eye, FDA Says
  • NT-219 Re-sensitizes Cancer to Keytruda, Stopping Tumor Progression, Study Shows
  • Opdivo Extends Survival, Has Less Impact on Lives in Head and Neck Cancer Patients Than Standard Chemo, Study Shows
  • Celgene Working with BeiGene to Develop Its PD-1 Inhibitor, BGB-A317, to Treat Solid Tumors
  • Phase 3 Trial to Assess Cabometyx Combo Therapies vs. Sutent in Advanced Kidney Cancer Patients
  • PDS, Merck to Launch Trial Testing Combo Therapy in Treating Certain Head and Neck Cancer Patients
  • $3.75 Million in Grants to Help ViraCyte Continue Working on Therapies to Combat Post-transplant Viruses
  • Gene Expression Analysis Helps Determine Sensitivity to Immunotherapies
  • Mirati Hosts Key Opinion Leader Breakfast on Immuno-oncology Combinations in NYC
  • Cancer Research Institute Announces $1 Million Technology Impact Award Winner
  • Opdivo Keeps Melanoma from Recurring Longer Than Yervoy, Phase 3 Clinical Trial Shows